Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Jiménez, Natalia
• dc.contributor.author Reig, Òscar
• dc.contributor.author Marín-Aguilera, Mercedes
• dc.contributor.author Aversa, Caterina
• dc.contributor.author Ferrer-Mileo, Laura
• dc.contributor.author Font, Albert
• dc.contributor.author Rodríguez-Vida, Alejo
• dc.contributor.author Climent, Miguel Ángel
• dc.contributor.author Cros, Sara
• dc.contributor.author Chirivella, Isabel
• dc.contributor.author Doménech, Montserrat
• dc.contributor.author Figols, Mariona
• dc.contributor.author González-Billalabeitia, Enrique
• dc.contributor.author Jiménez Peralta, Daniel
• dc.contributor.author Rodríguez-Carunchio, Leonardo
• dc.contributor.author García-Esteve, Samuel
• dc.contributor.author García de Herreros, Marta
• dc.contributor.author Ribal, Maria J.
• dc.contributor.author Prat, Aleix
• dc.contributor.author Mellado, Begoña
• dc.date.accessioned 2023-01-26T07:31:08Z
• dc.date.available 2023-01-26T07:31:08Z
• dc.date.issued 2022
• dc.description.abstract Background: androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts mHSPC evolution in a multicenter retrospective biomarker study. A customized panel of 184 genes was tested in mRNA from tumor samples by the nCounter platform in 125 mHSPC patients treated with ADT+DX. Gene expression was correlated with castration-resistant prostate cancer-free survival (CRPC-FS) and overall survival (OS). (3) Results: High expression of androgen receptor (AR) signature was independently associated with longer CRPC-FS (hazard ratio (HR) 0.6, 95% confidence interval (CI) 0.3-0.9; p = 0.015), high expression of estrogen receptor (ESR) signature with longer CRPC-FS (HR 0.6, 95% CI 0.4-0.9; p = 0.019) and OS (HR 0.5, 95% CI 0.2-0.9, p = 0.024), and lower expression of tumor suppressor genes (TSG) (RB1, PTEN and TP53) with shorter OS (HR 2, 95% CI 1-3.8; p = 0.044). ARV7 expression was independently associated with shorter CRPC-FS (HR 1.5, 95% CI 1.1-2.1, p = 0.008) and OS (HR 1.8, 95% CI 1.2-2.6, p = 0.004), high ESR2 was associated with longer OS (HR 0.5, 95% CI 0.2-1, p = 0.048) and low expression of RB1 was independently associated with shorter OS (HR 1.9, 95% CI 1.1-3.2, p = 0.014). (4) Conclusions: AR, ESR, and TSG expression signatures, as well as ARV7, RB1, and ESR2 expression, have a prognostic value in mHSPC patients treated with ADT+DX.
• dc.format.mimetype application/pdf
• dc.identifier.citation Jiménez N, Reig Ò, Marín-Aguilera M, Aversa C, Ferrer-Mileo L, Font A, et al. Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel. Cancers (Basel). 2022 Sep 29; 14(19): 4757. DOI: 10.3390/cancers14194757
• dc.identifier.doi http://dx.doi.org/10.3390/cancers14194757
• dc.identifier.issn 2072-6694
• dc.identifier.uri http://hdl.handle.net/10230/55438
• dc.language.iso eng
• dc.publisher MDPI
• dc.rights Copyright © 2022 by Jiménez N, Reig Ò, Marín-Aguilera M, Aversa C, Ferrer-Mileo L, Font A, et al. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Androgen receptor
• dc.subject.keyword Chemotherapy
• dc.subject.keyword Estrogen receptor
• dc.subject.keyword Hormonal therapy
• dc.subject.keyword Metastatic prostate cancer
• dc.subject.keyword Predictive biomarkers
• dc.subject.keyword Tumor suppressor genes
• dc.title Transcriptional profile associated with clinical outcomes in metastatic hormone-sensitive prostate cancer treated with androgen deprivation and docetaxel
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion